Citius Oncology (CTOR) Shares Outstanding (Weighted Average) (2021 - 2026)

Citius Oncology's Shares Outstanding (Weighted Average) history runs 6 years deep, the most recent figure standing at $100.0 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 39.8% year-over-year to $100.0 million; the TTM figure through Mar 2026 stood at $100.0 million (up 39.8% YoY), while the FY2025 annual figure was $13.3 million, down 80.49% from the prior year.
• Shares Outstanding (Weighted Average) was $100.0 million for Q1 2026 at Citius Oncology, up from $46.8 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $100.0 million in Q1 2026 to a low of $1.3 million in Q4 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $40.2 million across 5 years, with a median of $46.8 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Weighted Average) surged 4930.71% in 2023, then sank 80.49% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $1.3 million in 2022, then soared by 4930.71% to $67.5 million in 2023, then rose by 6.0% to $71.6 million in 2024, then slumped by 34.54% to $46.8 million in 2025, then jumped by 113.57% to $100.0 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $100.0 million (Q1 2026), $46.8 million (Q4 2025), and $13.3 million (Q3 2025), per Business Quant data.